Hims & Hers Shares Tumble Despite Strong Quarterly Growth

The investment community reacted with a sharp sell-off to Hims & Hers Health’s third-quarter earnings report released on November 3rd. The telehealth provider’s stock plummeted approximately 7.6%, a decline that starkly contrasted with its impressive top-line expansion. A deeper analysis reveals a challenging scenario where robust user growth is being offset by contracting profitability and a more cautious forward outlook, raising questions about the sustainability of its current trajectory.

Profitability Pressures Emerge

While the headline revenue figure was undoubtedly strong, climbing 49% year-over-year to reach $599 million, underlying financial health indicators presented a more nuanced picture. The company’s gross margin contracted significantly, falling to 74% from 79% in the prior-year period. This compression is largely attributed to strategic investments in the supply chain for its personalized GLP-1 weight loss medications.

The net income figure experienced an even more dramatic shift, dropping to $15.8 million from $75.6 million. It is important to contextualize this decline, as the previous year’s result was artificially inflated by a one-time tax benefit of $60.8 million. Elsewhere, the company reported a subscriber base of 2.47 million, representing a 21% increase, and an adjusted EBITDA of $78.4 million, a 53% year-over-year gain.

Key Financial Metrics at a Glance:

• Q3 Revenue: $599 Million (+49% Year-over-Year)
• Subscriber Count: 2.47 Million (+21% Year-over-Year)
• Gross Margin: 74% (Previous Year: 79%)
• Net Profit: $15.8 Million (Previous Year: $75.6 Million)
• Adjusted EBITDA: $78.4 Million (+53% Year-over-Year)

Cautious Guidance and Strategic Shifts

Market nervousness was further fueled by the company’s revised annual revenue forecast, which was modestly trimmed to a range of $2.335 billion to $2.355 billion. The full-year EBITDA expectation was maintained between $307 million and $317 million. For the critical fourth quarter, management projected revenue of $605 million to $625 million, accompanied by a notably thin EBITDA margin of just 9% to 10%.

Should investors sell immediately? Or is it worth buying Hims & Hers?

This tempered guidance arrives amid intensifying competition across the telehealth sector, particularly within the high-value weight management market. A potentially transformative development, however, is in the works. The company is in discussions with pharmaceutical titan Novo Nordisk to offer Wegovy injections and a potential future oral version, pending FDA approval, through its platform. This would mark a significant strategic pivot following the conclusion of a previous agreement set for June 2025.

A Company at a Crossroads

CEO Andrew Dudum has reaffirmed the long-term ambition of achieving $6.5 billion in revenue by 2030. Supporting this goal is the recent acquisition of the UK-based digital health platform Zava, which provides Hims & Hers with immediate access to key European markets including the United Kingdom, Germany, Ireland, and France.

The stock now finds itself at a pivotal juncture. On one hand, the business demonstrates compelling growth metrics and cross-selling success; over 20% of its customers now utilize the platform for multiple healthcare needs, and the average monthly revenue per subscriber jumped 19% to $80.

Conversely, the stock is weighed down by margin pressure, heightened investment spending, and an increasingly competitive landscape. Recent executive changes, including the transition of COO Nader Kabbani to an advisory role and the promotion of Chief Commercial Officer Mike Chi to the COO position, signal a renewed internal focus on operational efficiency.

The direction of the share price in the coming months will likely be determined by the success of these strategic initiatives and the materialization of the potential Novo Nordisk partnership. For now, an investment in Hims & Hers remains a calculated bet on the future of digital healthcare, embodying both significant promise and palpable risk.